

# Provider Readiness Guide



onpattro<sup>™</sup>  
(patisiran) lipid complex  
injection

# Alnylam Assist™ is here to help

**Alnylam Assist is dedicated to helping guide your patients through treatment with ONPATTRO™ (patisiran).**

Alnylam Assist offers a range of services to help with:

- Securing access to ONPATTRO for your patient
- Initiating treatment with ONPATTRO for your patient
- Facilitating product orders

For more information about how Alnylam Assist can help your patients, please see the **Services Overview Brochure** inside the ONPATTRO Access & Reimbursement Kit or visit [www.AlnylamAssist.com](http://www.AlnylamAssist.com).

## Preparing for the reimbursement process

**When considering whether to offer ONPATTRO to your patients, please refer to the steps below when setting up your office.**

### With your payers

1. Contact the payers you participate with (commercial, local Medicare Administrative Contractor, State Medicare, etc.) for additional information regarding appropriate coverage, coding, and payment policies for ONPATTRO.
  - Discuss the payment methodology for the appropriate unclassified Healthcare Common Procedure Coding System (HCPCS) code with commercial payers
2. Ensure that the clinical documentation for each patient is in accordance with payer-specific coverage requirements and key medical necessity criteria.

### With your practice

3. Know who in your practice is responsible for each of the following tasks:
  - Receiving benefit verification information
  - Submitting prior authorization/precertification, if required
  - Discussing financial obligations with patients
  - Scheduling appointments for ONPATTRO administration
  - Ordering ONPATTRO
  - Submitting claims to payers
4. Update charge master/electronic billing system to ensure that ONPATTRO is recognized.
5. Anticipate requests from payers for clinical documentation if filing claims for ONPATTRO.

The Alnylam Assist team includes **Field Reimbursement Directors** who are knowledgeable in chart documentation best practices and ONPATTRO billing and coding requirements.

**Please see Important Safety Information on the following pages and accompanying Full Prescribing Information.**

# Initiating therapy

When preparing to treat a patient with ONPATTRO™ at your practice, follow the steps below to help enable patient access, proper claims submission, and reimbursement.

1. Together with your patient, complete the Anylam Assist™ **Start Form** to initiate verification of benefits and/or an eligibility assessment for patient financial assistance, if required.
  - To access the Anylam Assist **Start Form**, visit [www.AnylamAssist.com](http://www.AnylamAssist.com). A printed copy of the Start Form can also be found in the ONPATTRO Access & Reimbursement Kit



To get started, go to [www.AnylamAssist.com](http://www.AnylamAssist.com) and complete the Anylam Assist **Start Form** with your patient.

2. Schedule the patient's ONPATTRO infusion.
  - Before your patient's first infusion, an Anylam team member will reach out to offer an on-site ONPATTRO preparation and administration educational in-service
3. Work with Anylam Assist to determine the method for ordering ONPATTRO.
  - The Anylam Assist team will help facilitate acquisition of ONPATTRO for your patient via specialty distributor or specialty pharmacy. For some patients, home infusion may also be an option
4. After treatment, complete and submit the claim to the payer.
  - Anylam Assist provides support through the claims submission process, including tracking the status of and providing updates on claims for your patient. Your practice will also have access to **Field Reimbursement Directors** who are available to meet with you and your staff to address reimbursement-related questions related to ONPATTRO

## Indication

ONPATTRO™ (patisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

## Important Safety Information

### Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTRO. In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed.

### Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

### Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

**Please see the accompanying Full Prescribing Information.**



8AM–7PM ET, Monday–Friday  
☎: 1-833-256-2748 | 📠: 1-833-256-2747

**To learn more about ONPATTRO™,  
visit [www.onpattro.com](http://www.onpattro.com).**